LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・TG Therapeutics Inc

TG Therapeutics Inc

Suletud

Sektor Tervishoid

22.04 3.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.84

Max

22.15

Põhinäitajad
By Trading Economics
Sissetulek	18M 6.9M
Müük	10M 73M
Aktsiakasum	0.04
Kasumimarginaal	9.364
Töötajad	264
EBITDA	-123M -8.3M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+59.78 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-170M 3.6B
Eelmine avamishind	19
Eelmine sulgemishind	22.04

Uudiste sentiment

By Acuity

50%

21 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

21.26 / 22.6 Toetus ja vastupanu

TG Therapeutics Inc Graafik

Seotud uudised

19. aug 2024, 20:01 UTC

Tulu

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Võrdlus sarnastega

Hinnamuutus

TG Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

59.78% tõus

12 kuu keskmine prognoos

Keskmine 35.2 USD 59.78%

Kõrge 49 USD

Madal 20 USD

Põhineb 5 Wall Streeti analüütiku instrumendi TG Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi TG Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

21.26 / 22.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

21 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest TG Therapeutics Inc

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).